Although many kinds of therapies are applied in the clinic, drug-resistance is a major and
unavoidable problem. Another disturbing statistic is the limited number of drug targets, which …

The tyrosine kinase inhibitors (TKIs) directed at sensitizing mutations in the epidermal
growth factor receptor (EGFR) gene represents a critical pillar in non-small cell lung cancer …

Purpose Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) have demonstrated potent activity against TKI resistance mediated by EGFR …

Anticancer therapies have been limited by the emergence of mutations and other
adaptations. In bacteria, antibiotics activate the SOS response, which mobilizes error-prone …

EGF receptor (EGFR)–mutant lung cancers eventually become resistant to treatment with
EGFR tyrosine kinase inhibitors (TKI). The combination of EGFR-TKI afatinib and anti-EGFR …

The ERBB family of receptor tyrosine kinases has a central role in the tumorigenesis of many
types of solid tumour. Various therapeutics targeting these receptors have been approved …

Lung cancer is the leading cause of cancer related deaths in Canada with non-small cell
lung cancer (NSCLC) being the predominant form of the disease. Tumor characterization …

The successes achieved by chimeric antigen receptor-modified T (CAR-T) cells in
hematological malignancies raised the possibility of their use in non-small lung cancer …

Small molecule covalent kinase inhibitors (CKIs) have entered a new era in drug discovery,
which have the advantage for sustained target inhibition and high selectivity. An increased …

Purpose EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here,
we present an update on new controversies and conclusions regarding the disease …